Article | 2026 ARVO

RESTORE Phase 2b/3 Trial Data Show Lasting BCVA Improvement in RP Patients

MCO-010 demonstrated sustained, clinically meaningful BCVA improvement over 3 years with favorable safety, supporting durable efficacy.